Search results
Showing 76 to 90 of 103 results for autologous
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Evidence-based recommendations on tocilizumab (RoActemra), for treating systemic juvenile idiopathic arthritis in people aged 2 and over.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please see NICE's HealthTech guidance 165 for the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE's HealthTech guidance 175 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.
This guidance has been updated and replaced by NICE HealthTech guidance 299.
Interventional procedures, IPG438 - Issued: January 2013 --> We have moved interventional procedures guidance 438 to become HealthTech guidance 299. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Interventional procedures, IPG437 - Issued: January 2013 --> We have moved interventional procedures guidance 437 to become HealthTech guidance 298. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
there isn't a short name for any of them. They are: : colposuspension : an autologous rectus fascial sling : a retropubic mid-urethral...
Autologous cartilage transplantation for full thickness cartilage defects in knee joints (TA16)
This guidance has been replaced by NICE technology appraisal guidance 89 [Replaced by NICE technology appraisal guidance 477].
We have moved interventional procedures guidance 274 to become HealthTech guidance 175. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
We have moved interventional procedures guidance 769 to become HealthTech guidance 689. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.